NCT07134335View on ClinicalTrials.gov

UBT251 Injection Phase II Clinical Study (CKD)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 11, 2025

Primary Completion Date

July 11, 2030

Study Completion Date

July 11, 2030

Conditions
Obesity &Amp; OverweightChronic Kidney Disease
Interventions
DRUG

UBT251

Subcutaneous injection once weekly

DRUG

UBT251

Subcutaneous injection once weekly

DRUG

UBT251

Subcutaneous injection once weekly

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

All Listed Sponsors
lead

The United Bio-Technology (Hengqin) Co., Ltd.

INDUSTRY

NCT07134335 - UBT251 Injection Phase II Clinical Study (CKD) | Biotech Hunter | Biotech Hunter